W. David Arnold said aging muscle loses strength partly because nerve-to-muscle communication becomes less reliable, and the University of Missouri reported that partially inhibiting ClC-1 improved strength in an animal model. The work points to a way of making existing muscle fibers more responsive rather than replacing lost tissue, with testing in older adults still ahead.
For more than 10 years, Arnold has studied the neuromuscular junction at the School of Medicine. He said, "While the human lifespan has increased in recent decades, our ultimate goal at Mizzou is to ensure a person's health span remains as high as possible for as long as possible," and added, "The significance of this new study is we are showing, in both humans and in animal models, that the neuromuscular junction is failing with aging."
University of Missouri findings
The researchers linked the problem to lower levels of NaV1.4, a protein that helps muscle fibers respond to signals from nerves. They also said the breakdown in nerve-to-muscle communication contributes to sarcopenia, which affects nearly half of adults older than 80.
Scientists have spent decades trying to understand why physical strength declines with age. Much of the earlier work focused on loss of muscle mass or on neurons that send signals needed to activate muscles. This study adds a different step in the chain: the final handoff between nerve and muscle.
ClC-1 in older muscle
Arnold said, "A long-held assumption in the field was that the neuromuscular junction remains reliable during aging, and some even suggested it may get better with aging," but the new research says it does not. He said, "We identified an important point of failure at the final step in communication between nerves and muscles," and, "And what is perhaps even more exciting is that we showed this failure is potentially reversible."
In collaboration with NMD Pharma, the researchers used an approach that targets ClC-1. Partially inhibiting ClC-1 made aging muscles more responsive to nerve signals in an animal model and improved muscle strength. One related piece of work on muscle injury also points to how specific muscle problems can shape recovery, as shown in Johnny Newton torn pectoral muscle leaves Tony Jefferson-era depth questions for Washington Commanders.
ClC-1 evidence in people
The article says there is already clinical evidence that targeting ClC-1 can improve some measures of muscle strength and function in people. That puts the work beyond a purely laboratory finding and moves it toward a path that still needs testing in older adults before anyone can know how well it will translate there.
The immediate takeaway for readers with sarcopenia is that the study does not point to rebuilding lost muscle from scratch. It points to a way of improving the signals existing muscle fibers receive, and the next step is whether that response holds in older adults as well as it did in the animal model.
